Study Of Remission In Patients Treated For Generalized Anxiety Disorder

An Observational Study of Remission in Patients Treated for Generalized Anxiety Disorder in Primary and Specialized Care in Belgium.

The aim of the study is to assess the remission rates in patients treated for generalized anxiety disorder in primary and specialized care. Factors that may influence remission such as disease history and severity of the anxiety disorder, the type of treatment, the presence of co-morbid depression or anxiety disorder as well as socio-demographic factors will also be evaluated. The study will also assess patient functioning and compare functioning in patients who do and do not achieve remission.

Study Overview

• Status: Completed
• Conditions: Anxiety Disorders
• Intervention / Treatment: Other: remission prevalence of generalized anxiety disorder

Detailed Description

The aim of the study is to assess the remission rates in patients treated for generalized anxiety disorder in primary and specialized care. Factors that may influence remission such as disease history and severity of the anxiety disorder, the type of treatment, the presence of co-morbid depression or anxiety disorder as well as socio-demographic factors will also be evaluated. The study will also assess patient functioning and compare functioning in patients who do and do not achieve remission.

The objectives of the study are:

Primary: To determine the prevalence of remission in patients treated for generalized anxiety disorder in primary care and specialized care. Secondary: To determine patient functioning and work loss days and compare these in patients who do or do not achieve remission. To determine the effect of disease factors on remission rate such as disease history, duration, severity, co-morbidity with depression or other anxiety disorders. To determine the effect of treatment factors on remission rate such as setting, type of treatment, duration and adherence. To determine the effect of socio-demographic factors on remission rate such as gender, age, region (language), marital status, educational level and employment status.

This will be a cross-sectional observational study looking at the point prevalence of remission in treated patients with generalized anxiety disorder in general practice and specialized care in Belgium. General practitioners and psychiatrists will assess remission rates in patients treated for generalized anxiety disorder during 1 routine visit of these patients.

The participating physicians will have 3 months to evaluate remission at a routine visit in 5 to 10 patients that have been treated for generalized anxiety disorder since at least 3 months

• Study Type: Observational
• Enrollment (Actual): 750

Contacts and Locations

Study Locations

• Belgium
  • Brussel, Belgium
    • Pfizer Inc.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

Patients treated with generalized anxiety disorder in primary and specialized care in Belgium.

Description

Inclusion criteria:

To be eligible the patient must meet all of the following:

1. Being treated for generalized anxiety disorder for approximately 3 months and not more than 12 months
2. Be at least 18 years of age;
3. Written informed consent
4. Out-patient

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
patients with generalized anxiety disorder	Other: remission prevalence of generalized anxiety disorder

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
remission of generalized anxiety disorder	5 months

Secondary Outcome Measures

Outcome Measure	Time Frame
determine the effect of disease and treatment factors on remission rates	5 months

Collaborators and Investigators

• Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Study record dates

Study Major Dates

• Study Start (Actual): March 1, 2006
• Primary Completion (Actual): March 1, 2006
• Study Completion (Actual): March 1, 2007

Study Registration Dates

• First Submitted: July 6, 2009
• First Submitted That Met QC Criteria: February 8, 2013
• First Posted (Estimate): February 11, 2013

Study Record Updates

• Last Update Posted (Actual): May 3, 2022
• Last Update Submitted That Met QC Criteria: April 28, 2022
• Last Verified: April 1, 2022

More Information

Terms related to this study

• Keywords: remission; generalized anxiety disorder
• Additional Relevant MeSH Terms: Mental Disorders; Pathologic Processes; Disease; Anxiety Disorders
• Other Study ID Numbers: 0600B-102246; B2411129 (Other Identifier: Pfizer)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No